By John Carroll With close to $800 million in the bank and an ambitious crew of executives now in charge, Biogen Idec’s research chief says the big biotech is actively hunting out new acquisitions and licensing deals. In an interview with Bloomberg, Doug Williams–the former head of ZymoGenetics until BMS bought the company out–highlighted Biogen’s interest …
By John Carroll Rockville, MD-based Sequella has completed a round of high-fives with leaders of the region’s biotech community after inking a licensing pact covering Russia and surrounding states for its mid-stage tuberculosis treatment. Sequella boasts that the deal is potentially worth up to $50 million, though it didn’t break down the equity investment, trial …
By John Carroll Biogen Idec’s new CEO, George Scangos (photo), is prepared to bring out the company’s check book to build up its franchise of new drugs for noncancerous diseases of the blood. The big biotech, which has two new drugs for hemophilia in late-stage development, is looking to add to the portfolio by in-licensing or …
By John Carroll With all the buzz last week about Sanofi’s new Covance deal and its ongoing struggle to gain control of Genzyme, it was easy to overlook CEO Chris Viehbacher’s pipeline review for the Big Pharma company. Viehbacher has been engaged in a head-to-toe revamp of R&D from his first day at the helm. Late last …
